A0A2R9CKP4 (A0A2R9CKP4_PANPA) Pan paniscus (Pygmy chimpanzee) (Bonobo)
Protein cereblon UniProtKBInterProInteractive Modelling
442 aa; Sequence (Fasta) ;
3 identical sequences: Homo sapiens: Q96SW2; Pan troglodytes: H2R8H3, A0A6D2W501
Available Structures
48 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of the DDB1-CRBN-pomalidomide complex bound to ZNF692(ZF4) |
Heteromer Q16531; Q96SW2; Q9BU19; | 100 | 2×ZN; 1×Y70; | |||
| Crystal structure of human CRBN-DDB1 in complex with Pomalidomide |
Heteromer Q16531; Q96SW2; | 100.0 | 6×EDO; 1×ZN; 1×Y70; | |||
| Cereblon in complex with DDB1, CC-90009, and GSPT1 |
Heteromer P15170; Q16531; Q96SW2; | 100.0 | 1×V4M; 1×ZN; | |||
| Cereblon in complex with DDB1, CC-885, and GSPT1 |
Heteromer P15170; Q16531; Q96SW2; | 100.0 | 1×ZN; 1×85C; | |||
| Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase |
Heteromer P48729; Q16531; Q96SW2; | 100.0 | 1×ZN; 1×LVY; | |||
| Crystal structure of DDB1-CRBN-ALV1 complex bound to Helios (IKZF2 ZF2) |
Heteromer Q16531; Q96SW2; Q9UKS7; | 100.0 | 2×ZN; 1×RN9; | |||
| Degrader-induced complex between PTPN2 and CRBN-DDB1 |
Heteromer P17706; Q16531; Q96SW2; | 100 | 1×WO8; 1×ZN; | |||
| Crystal structure of human CRBN-DDB1 in complex with compound 4 |
Heteromer Q16531; Q96SW2; | 100.0 | 9×EDO; 1×ZN; 1×VP9; | |||
| Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET6 PROTAC. |
Heteromer O60885; Q16531; Q96SW2; | 100.0 | 1×ZN; 1×RN6; | |||
| Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET23 PROTAC. |
Heteromer O60885; Q16531; Q96SW2; | 100.0 | 1×ZN; 1×RN3; | |||
| Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET55 PROTAC. |
Heteromer O60885; Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET70 PROTAC |
Heteromer O60885; Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 2 |
Heteromer Q13422; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×MIQ; | |||
| Cereblon~DDB1 bound to CC-92480 with DDB1 in the twisted conformation |
Heteromer Q16531; Q96SW2; | 100 | 1×ZN; 1×QFC; | |||
| Cereblon~DDB1 bound to CC-92480 with DDB1 in the linear conformation |
Heteromer Q16531; Q96SW2; | 100 | 1×ZN; 1×QFC; | |||
| Cereblon~DDB1 bound to CC-92480 with DDB1 in the hinged conformation |
Heteromer Q16531; Q96SW2; | 100 | 1×ZN; 1×QFC; | |||
| Crystal structure of PROTAC CFT-1297 in complex with CRBN-midi and BRD4(BD2) |
Heteromer O60885; Q96SW2; | 97.22 | 1×A1H2F; 1×ZN; | |||
| Cereblon in complex with DDB1 and CC-220 |
Heteromer Q16531; Q96SW2; | 100.0 | 1×8W7; 1×ZN; | |||
| Structure with SJ3149 |
Heteromer P48729; Q16531; Q96SW2; | 100.0 | 1×ZN; 1×YOT; | |||
| Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide |
Heteromer Q16531; Q96SW2; | 100.0 | 1×ZN; 1×LVY; | |||
| Cereblon~DDB1 bound to Pomalidomide |
Heteromer Q16531; Q96SW2; | 100 | 1×ZN; 1×Y70; | |||
| Cereblon-DDB1 bound to CC-92480 and Ikaros ZF1-2-3 |
Heteromer Q13422; Q16531; Q96SW2; | 100 | 2×ZN; 1×QFC; | |||
| Cereblon~DDB1 bound to Iberdomide and Ikaros ZF1-2-3 |
Heteromer Q13422; Q16531; Q96SW2; | 100 | 2×ZN; 1×8W7; | |||
| Structural Basis for Thalidomide Teratogenicity Revealed by the Cereblon-DDB1-SALL4-Pomalidomide Co… |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 100.0 | 2×ZN; 1×Y70; | |||
| Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 1 |
Heteromer Q13422; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×MIQ; | |||
| Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2) and the molecular glue DKY709 |
Heteromer Q16531; Q53SU9; Q96SW2; | 100 | 2×ZN; 1×LWK; 4×SO4; | |||
| Structure of DDB1-CRBN-pomalidomide complex bound to IKZF1(ZF2) |
Heteromer Q13422; Q16531; Q96SW2; | 100 | 2×ZN; 1×Y70; | |||
| Crystal structure of CRBN-midi in complex with mezigdomide and IKZF1 ZF2 |
Heteromer Q13422; Q96SW2; | 96.67 | 4×ZN; 2×QFC; | |||
| Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2,3) and the molecular glue DKY709 |
Heteromer Q16531; Q96SW2; Q9UKS7; | 100 | 3×ZN; 1×LWK; | |||
| The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to CC-220 |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 100.0 | 3×ZN; 1×8W7; 6×SO4; | |||
| Ternary complex structure of Cereblon-DDB1 bound to WIZ(ZF7) and the molecular glue WIZ-5 |
Heteromer O95785; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×SO4; 1×A1A5H; | |||
| Ternary complex structure of Cereblon-DDB1 bound to WIZ(ZF7) and the molecular glue WIZ-6 |
Heteromer O95785; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×SO4; 1×A1A5I; | |||
| Cereblon-DDB1 in the Apo form with DDB1 in the twisted conformation |
Heteromer Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| Cereblon-DDB1 in the Apo form |
Heteromer Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| Cereblon~DDB1 in the Apo form with DDB1 in the hinged conformation |
Heteromer Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET57 PROTAC |
Heteromer O60885; Q16531; Q96SW2; | 100.0 | 1×ZN; | |||
| The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to Pomalidomide |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 100.0 | 3×ZN; 1×Y70; | |||
| The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-long bound to Pomalidomide |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 100.0 | 3×ZN; 1×Y70; | |||
| Ternary complex structure of Cereblon-DDB1 bound to WIZ(ZF7) and the molecular glue dWIZ-1 |
Heteromer O95785; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×U3I; 2×SO4; 1×EDO; | |||
| Cryo-EM structure of DDB1dB:CRBN:Pomalidomide:SD40 |
Heteromer Q13422; Q16531; Q96SW2; | 100.0 | 2×ZN; 1×Y70; | |||
| Cereblon in complex with SALL4 and (S)-5-hydroxythalidomide |
Heteromer Q96SW2; Q9UJQ4; | 99.08 | 1×F4U; 2×ZN; 2×SO4; | |||
| Cereblon in complex with SALL4 and (S)-thalidomide |
Heteromer Q96SW2; Q9UJQ4; | 99.08 | 1×EF2; 2×ZN; | |||
| crystal structure of hN33/Tusc3-peptide 1 |
Heteromer Q13454; Q96SW2; | 100 | ||||
| Crystal structure of CRBN with compound 3 | homo-3-mer | 100.0 | 3×ZN; 3×A1A0J; 8×SO4; 2×EDO; | |||
| Crystal structure of CRBNmidi in complex with 2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)-N-methylacetam… | homo-2-mer | 97.16 | 2×A1IJM; 2×ZN; | |||
| Crystal structure of CRBN-midi in complex with mezigdomide | monomer | 97.06 | 1×ZN; 1×QFC; | |||
| Crystal structure of CRBN-midi in complex with Lenalidomide | monomer | 96.97 | 1×LVY; 1×ZN; | |||
| Crystal structure of CRBN-midi | monomer | 96.55 | 1×ZN; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8tnr.1.B | monomer | 0.81 | 1×ZN; | 100.00 | ||
| 8cvp.1.B | monomer | 0.70 | 1×ZN; | 100.00 | ||